AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Characterization of the newly proposed HIV-1 lineage within subtype A, sub-subtype A7View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Association of APOBEC3 activity in HIV-1 DNA with non-B HIV-1 and low HIV-1 reservoirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021PK-virological algorithm to target risk of resistance among key populations in TogoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Longitudinal Evaluation of Sequencing Quality in EQA-Schemes from 2014 to 2020View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Use of Fibroquel® (type I polymerized collagen) in patients with hypoxemic inflammatory pneumonia secondary to COVID-19 in Veracruz, Mexico.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021A Multi-Allelic Molecular-Beacon-Based Real-Time RT-PCR Assay for the Detection of the Coronavirus SARS-CoV-2 from Clinical SamplesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically-suppressed patients included in the ANRS LAMIDOL trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Usefulness of next-generation sequencing on PBMC samples and HIV-1 DNA quantification in management of treatment optimization in HIV-1 infected virologically suppressed individualsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG+3TC or ATV/r+3TC dual therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Exploration of the possible mechanisms leading to greater mortality in people with limited drug options (LDO)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Determinants of HIV-1 late presentation in patients followed in EuropeView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE StudyView Abstract
